Neotigason (Acitretin)

Acitretin, the active ingredient in Neotigason, is a retinoid presented as an oral capsule for oral use. It is indicated for the treatment of severe psoriasis and certain disorders of keratinization such as ichthyosis, primarily in adult patients, and is employed when topical therapies are insufficient.

GNH USA supplies Neotigason as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU regulatory standards and is distributed under strict quality controls. Manufacturing follows GMP guidelines to ensure batch consistency.

Neotigason, a systemic retinoid, is used to manage disorders of keratinocyte proliferation and differentiation.

Severe psoriasis: reduces plaque formation and scaling in patients with extensive disease. Ichthyosis: normalizes skin shedding and improves barrier function in inherited keratinization disorders. Palmoplantar keratoderma: decreases hyperkeratosis on palms and soles, improving mobility and comfort.

Acitretin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dry skin: excessive epidermal dryness and scaling. - Cheilitis: inflammation and cracking of the lips. - Elevated triglycerides: increase in serum triglyceride levels. - Headache: mild to moderate cephalic discomfort.

Serious or Rare Side Effects: - Hepatotoxicity: significant elevation of liver enzymes or liver injury. - Pseudotumor cerebri: increased intracranial pressure presenting with headache and visual changes. - Severe hyperlipidemia: marked rise in cholesterol or triglycerides requiring medical intervention.

Before initiating acitretin therapy, several safety considerations should be observed.

Teratogenicity: avoid use in pregnancy and ensure effective contraception for at least 3 years after discontinuation. Liver function: monitor hepatic enzymes regularly due to risk of hepatotoxicity. Lipid profile: assess serum triglycerides and cholesterol before and during treatment. Bone health: use cautiously in patients with pre‑existing skeletal disorders or osteoporosis. Concomitant vitamin A: do not combine with other vitamin A derivatives to prevent additive toxicity. Store below 25°C: keep in the original pack, protect from moisture.

Acitretin can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Tetracyclines: increased risk of intracranial hypertension. - Vitamin A supplements: additive retinoid toxicity. - Oral estrogen therapy: may reduce acitretin effectiveness.

Moderate Interactions (Monitor Closely): - Statins: potential for exacerbated hyperlipidemia. - Systemic corticosteroids: heightened risk of lipid abnormalities. - Warfarin: possible alteration of anticoagulant effect.